| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Amlodipine[1] | Calcium channel blocker (DHP) | 5 mg PO once daily, up-titrate to 10 mg if BP not at target after 4 weeks | — | First step in WHO HEARTS protocol; most countries initiate amlodipine alone or in combination |
| Telmisartan or enalapril[1] | ARB or ACE inhibitor | Telmisartan 40–80 mg PO daily; enalapril 5–40 mg PO daily (divided BD if higher dose) | — | Second step partner with amlodipine; ACE-i / ARB choice based on availability and tolerance |
| Hydrochlorothiazide[1] | Thiazide diuretic | 12.5–25 mg PO once daily | — | Third agent when dual therapy insufficient; cost-effective and widely available |
| Spironolactone[1] | Mineralocorticoid receptor antagonist | 12.5–50 mg PO once daily | — | Fourth-line for resistant hypertension; monitor potassium and creatinine |
Pharmacological treatment of hypertension per the WHO HEARTS technical package — protocol-based management for primary care in low- and middle-income settings.